Related references
Note: Only part of the references are listed.Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
Holly K. Koblish et al.
MOLECULAR CANCER THERAPEUTICS (2010)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Loeb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Prevention of Spontaneous Tumor Development in a ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan
Jun Zeng et al.
CANCER RESEARCH (2009)
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Feng Qian et al.
CANCER RESEARCH (2009)
A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
Meng-Chi Yen et al.
CLINICAL CANCER RESEARCH (2009)
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Helen J. Ball et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model
Eddy W. Yue et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-γ
Selim Corm et al.
LEUKEMIA RESEARCH (2009)
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Loeb et al.
NATURE REVIEWS CANCER (2009)
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection
Agnes Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
Alexander J. Muller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT
Xueling Ou et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Stefan Lob et al.
BLOOD (2008)
Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4+ and CD8+ T cells
Farshad Forouzandeh et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2008)
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
Richard Metz et al.
CANCER RESEARCH (2007)
Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer
Takafumi Nakamura et al.
CANCER SCIENCE (2007)
Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells
In Duk Jung et al.
FEBS LETTERS (2007)
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells
Antonio Curti et al.
BLOOD (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients
Georg Weinlich et al.
DERMATOLOGY (2007)
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
K. Ino et al.
BRITISH JOURNAL OF CANCER (2006)
A high-affinity, tryptophan-selective amino acid transport system in human macrophages
Robert L. Seymour et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference
Xiufen Zheng et al.
JOURNAL OF IMMUNOLOGY (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
1-methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity
Sophie Agaugue et al.
JOURNAL OF IMMUNOLOGY (2006)
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells
Francesca Fallarino et al.
JOURNAL OF IMMUNOLOGY (2006)
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab
Xiangdong Liu et al.
CANCER BIOLOGY & THERAPY (2006)
Regulatory T cells, tumour immunity and immunotherapy
WP Zou
NATURE REVIEWS IMMUNOLOGY (2006)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
AM Ercolini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer
S Astigiano et al.
NEOPLASIA (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
IDO expression by dendritic cells: Tolerance and tryptophan catabolism
AL Mellor et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion
AL Mellor et al.
JOURNAL OF IMMUNOLOGY (2003)
What's the difference between CD80 and CD86?
DM Sansom et al.
TRENDS IN IMMUNOLOGY (2003)
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection
M Friberg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer
A Huang et al.
BRITISH JOURNAL OF CANCER (2002)
Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor
JE Thompson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity
GJ Logan et al.
IMMUNOLOGY (2002)
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation
P Hwu et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
